Credit Suisse Downgrades McKesson (MCK) to Underperform
- Wall Street gains, helped by oil, economic data
- Twitter (TWTR) 'Takeover Money' Moves On as 'Trump Money' Moves In
- Buy Any Seasonal Market Weakness Ahead of Year End Rally - Oppenheimer (SPY)
- Unusual 11 Mid-Day Movers 12/5: (NVCN) (BCEI) (MEMP) Higher; (GTXI) (CERC) (HDSN) Lower
- Oil hits 16-month high in buying rush after OPEC agreement
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Credit Suisse downgraded McKesson (NYSE: MCK) from Neutral to Underperform with a price target of $131.00 (from $150.00) on capital efficiency discrepancy.
Analyst Robert Willoughby commented, "MCK pointed to irrational industry pricing for a second negative EPS revision this year. AmerisourceBergen and Cardinal Health also noted weaker pricing, but with competitive advantages in generic sourcing capabilities from an invested capital standpoint, their practices seem more consistent with maintaining high ROICs. MCK's average invested capital base equals the sum for its two competitors, yet its NOPAT grew at about half the CAGR over FY12-FY16, with higher capital requirements and lower earnings ahead, in our view. Longer term, it may benefit more from owning sourcing capabilities outright, but Celesio contributions, higher deal spend/capital needs, and distortions from the pending Technology Solutions exit limit our near term enthusiasm."
Shares of McKesson closed at $141.33 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Goldman Sachs Downgrades Marvell (MRVL) to Sell
- KLR Group Raises Price Target on PDC Energy (PDCE) to $90
- Instinet Raises Price Target on Noble Energy (NBL) to $44; Reiterates Buy
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Downgrades, Hot Downgrades
Related EntitiesCredit Suisse, Earnings, Robert Willoughby
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!